2024
Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma
Su D, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. JCO Precision Oncology 2024, 8: e2300702. PMID: 38662983, PMCID: PMC11513442, DOI: 10.1200/po.23.00702.Peer-Reviewed Original ResearchConceptsMC1R expressionMelanoma progressionAssociated with shorter survivalStages of melanoma progressionCases of benign neviChronic sun exposureMarkers of progressionHuman melanoma tissuesBreslow thicknessMelanocortin-1Metastatic melanomaOverall survivalPrimary melanomaMetastatic tumorsMelanoma cohortReceptor expressionPredictive biomarkersAggressive melanomaPrimary lesionTissue microarrayShorter survivalMale sexQuantitative immunofluorescenceBenign neviClinical trials
2021
Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally
Esposito A, Jacobs D, Ariyan S, Galan A, Kluger H, Clune J, Weiss S, Tran T, Olino K. Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally. Annals Of Surgical Oncology 2021, 29: 415-424. PMID: 34494169, PMCID: PMC8677689, DOI: 10.1245/s10434-021-10727-2.Peer-Reviewed Original ResearchConceptsDisease-specific survivalOverall survivalCT2 diseasePractice patternsSingle-institution retrospective reviewShorter disease-specific survivalActive cigarette smokersAdoption of immunotherapyMultivariable Cox regressionUse of immunotherapyUse of radiotherapyResultsOne hundred fiftyShorter overall survivalAggressive neuroendocrine carcinomaRisk of mortalitySurrogate outcome measureBackgroundMerkel cell carcinomaTreatment of MCCMCC managementImmunocompromised stateMCC patientsMedian ageUnknown primaryRetrospective reviewCigarette smokersAssessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States
Jacobs D, Huang H, Olino K, Weiss S, Kluger H, Judson BL, Zhang Y. Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States. JAMA Dermatology 2021, 157: 59-65. PMID: 33146688, PMCID: PMC7643047, DOI: 10.1001/jamadermatol.2020.4102.Peer-Reviewed Original ResearchConceptsMerkel cell carcinomaBirth cohort effectsCell carcinomaIncidence rateCalendar periodBirth cohortPatient ageNew casesCohort effectsEnd Results Program databaseCross-sectional retrospective studyLongitudinal cohort studyHigh incidence rateAge-adjusted ratesRisk factor exposureRecent birth cohortsCohort studyCarcinoma incidenceRetrospective studyNeuroendocrine cancerAge effectsProgram databaseCohort analysisMAIN OUTCOMECarcinoma
2020
Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck
Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology 2020, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.Peer-Reviewed Original ResearchConceptsNode-negative Merkel cell carcinomaLymph node evaluationImproved overall survivalPrimary tumor excisionMerkel cell carcinomaCase volumeOverall survivalSurgical managementCell carcinomaTumor excisionTreatment selectionNode evaluationCox proportional hazards regressionGuideline-recommended carePrimary treatment selectionNational Cancer DatabaseNode-negative diseasePercentage of patientsRetrospective cohort analysisInitial surgical managementKaplan-Meier analysisWide local excisionProportional hazards regressionRates of receiptInitial managementSurvival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Klemen ND, Wang M, Rubinstein JC, Olino K, Clune J, Ariyan S, Cha C, Weiss SA, Kluger HM, Sznol M. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: e000341. PMID: 32209601, PMCID: PMC7103823, DOI: 10.1136/jitc-2019-000341.Peer-Reviewed Original ResearchConceptsCheckpoint inhibitorsOverall survivalMetastatic melanomaPrimary tumorLocal therapyCutaneous melanomaAnti-PD-1 antibodyAggressive multidisciplinary approachCutaneous primary tumorPrimary tumor histologyMedian overall survivalSingle institutional experienceRare melanoma subtypeMedian OSMetastatic diseaseProgressive diseaseAcral skinComplete responsePD-1PD-L1Uveal tractTumor histologyCombination therapyCTLA-4Longer survival
2019
PD-1 Blockade in Advanced Adrenocortical Carcinoma.
Raj N, Zheng Y, Kelly V, Katz SS, Chou J, Do RKG, Capanu M, Zamarin D, Saltz LB, Ariyan CE, Untch BR, O'Reilly EM, Gopalan A, Berger MF, Olino K, Segal NH, Reidy-Lagunes DL. PD-1 Blockade in Advanced Adrenocortical Carcinoma. Journal Of Clinical Oncology 2019, 38: 71-80. PMID: 31644329, PMCID: PMC7351334, DOI: 10.1200/jco.19.01586.Peer-Reviewed Original ResearchConceptsAdvanced adrenocortical carcinomaObjective response rateAdrenocortical carcinomaObjective responseResponse rateMedian progression-free survivalMismatch repair-deficient statusTreatment-related grade 3Disease control rateManageable safety profileMedian overall survivalPD-1 blockadePercent of patientsPhase II studyPrimary end pointProgression-free survivalDurable antitumor activityLimited treatment optionsMicrosatellite stable tumorsPrior therapyAdverse eventsII studyMedian durationOverall survivalStandard therapyPatterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 196. PMID: 31340861, PMCID: PMC6657062, DOI: 10.1186/s40425-019-0672-3.Peer-Reviewed Original ResearchConceptsThree-year progression-free survivalProgression-free survivalDisease-specific survivalFive-year disease-specific survivalPatterns of failureDurable progression-free survivalLocal therapyStereotactic body radiotherapyMetastatic melanomaNew metastasesPatient selectionIndependent radiological reviewOngoing complete responseResultsFour hundred twentyEvidence of diseaseCNS metastasisCPI treatmentImmunotherapy failureCheckpoint inhibitorsMost patientsProgressive diseaseRadiological reviewComplete responsePD-1PD-L1Prevalence of False-Negative Results of Intraoperative Consultation on Surgical Margins During Resection of Gastric and Gastroesophageal Adenocarcinoma
McAuliffe JC, Tang LH, Kamrani K, Olino K, Klimstra DS, Brennan MF, Coit DG. Prevalence of False-Negative Results of Intraoperative Consultation on Surgical Margins During Resection of Gastric and Gastroesophageal Adenocarcinoma. JAMA Surgery 2019, 154: 126-132. PMID: 30422226, PMCID: PMC6439656, DOI: 10.1001/jamasurg.2018.3863.Peer-Reviewed Original ResearchConceptsCurative-intent resectionSurgical marginsIOC resultsGastroesophageal adenocarcinomaNeoadjuvant radiotherapyIntraoperative consultationFN resultsClinical implicationsDuodenal marginsFalse-negative resultsSingle institution referral centerResection of gastricDisease-specific survivalStage of diseaseTrue-positive resultsGastric marginSurgical fitnessCurative intentReferral centerSubsequent resectionEsophageal resectionRetrospective studyGastrointestinal pathologistsDiffuse diseaseTumor location
2016
Incidence of hepaticojejunostomy stricture after hepaticojejunostomy
Dimou FM, Adhikari D, Mehta HB, Olino K, Riall TS, Brown KM. Incidence of hepaticojejunostomy stricture after hepaticojejunostomy. Surgery 2016, 160: 691-698. PMID: 27392391, PMCID: PMC5429863, DOI: 10.1016/j.surg.2016.05.021.Peer-Reviewed Original ResearchConceptsBiliary-enteric anastomosisStricture formationBiliary-enteric anastomotic stricturesCox proportional hazards modelManagement of stricturesProportional hazards modelCumulative incidence curvesMedicare claims dataUse of imagingStricture diagnosisCumulative incidenceAnastomotic strictureHepaticojejunostomy stricturesPostoperative strictureTrue incidenceClaims dataHazards modelPatientsStrictureAnastomosisDecreased likelihoodYounger ageIncidence curvesIncidenceMean timeLonger Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer
Faisal F, Tsai HL, Blackford A, Olino K, Xia C, De Jesus-Acosta A, Le DT, Cosgrove D, Azad N, Rasheed Z, Diaz LA, Donehower R, Laheru D, Hruban RH, Fishman EK, Edil BH, Schulick R, Wolfgang C, Herman J, Zheng L. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. American Journal Of Clinical Oncology 2016, 39: 18-26. PMID: 24351782, PMCID: PMC4061284, DOI: 10.1097/coc.0000000000000022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemoradiotherapyCohort StudiesDeoxycytidineDisease-Free SurvivalFemaleFluorouracilGemcitabineHumansInduction ChemotherapyMaleMiddle AgedNeoplasm StagingPancreatic NeoplasmsProportional Hazards ModelsRetrospective StudiesSex FactorsTime FactorsTreatment OutcomeConceptsAdvanced pancreatic cancerCycles of chemotherapyOverall survivalInduction chemotherapyPancreatic cancerMedian overall survivalRole of chemotherapyTreatment of LAPCUnresectable stage 3Better survival outcomesBetter overall survivalCombination of chemotherapyJohns Hopkins HospitalSensitization of tumorsConsolidative chemoradiationSubsequent chemoradiationCombination chemotherapyCumulative incidenceProspective studySurvival outcomesStandard treatmentDisease progressionChemoradiationRetrospective analysisChemotherapy
2014
A Single Institution's 26-Year Experience With Nonfunctional Pancreatic Neuroendocrine Tumors
Ellison TA, Wolfgang CL, Shi C, Cameron JL, Murakami P, Mun LJ, Singhi AD, Cornish TC, Olino K, Meriden Z, Choti M, Diaz LA, Pawlik TM, Schulick RD, Hruban RH, Edil BH. A Single Institution's 26-Year Experience With Nonfunctional Pancreatic Neuroendocrine Tumors. Annals Of Surgery 2014, 259: 204-212. PMID: 23673766, PMCID: PMC4048026, DOI: 10.1097/sla.0b013e31828f3174.Peer-Reviewed Original ResearchConceptsPancreatic neuroendocrine tumorsStaging systemSimple prognostic toolNeuroendocrine tumorsPrognostic toolStage IFive-year overall survival rateNonfunctional pancreatic neuroendocrine tumorsMain staging systemsAJCC stage ITumor staging systemOverall survival rateAmerican Joint CommitteeSingle-institution seriesKi-67 labelingPrognostic factorsSurvival prognosticationSingle institutionJoint CommitteeMultivariate analysisNatural historyComparison of reportsPatientsNeoplasmsSurvival
2012
Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas
Matthaei H, Norris AL, Tsiatis AC, Olino K, Hong SM, dal Molin M, Goggins MG, Canto M, Horton KM, Jackson KD, Capelli P, Zamboni G, Bortesi L, Furukawa T, Egawa S, Ishida M, Ottomo S, Unno M, Motoi F, Wolfgang CL, Edil BH, Cameron JL, Eshleman JR, Schulick RD, Maitra A, Hruban RH. Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals Of Surgery 2012, 255: 326-333. PMID: 22167000, PMCID: PMC3534752, DOI: 10.1097/sla.0b013e3182378a18.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, MucinousAgedAged, 80 and overCarcinoma, Pancreatic DuctalCarcinoma, PapillaryClone CellsFemaleHumansLaser Capture MicrodissectionLoss of HeterozygosityMaleMiddle AgedMutationNeoplasms, Multiple PrimaryNeoplasms, Second PrimaryPancreatic NeoplasmsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRetrospective StudiesSequence Analysis, DNAConceptsMultifocal intraductal papillary mucinous neoplasmsIntraductal papillary mucinous neoplasmPapillary mucinous neoplasmMucinous neoplasmsClinicopathologic featuresPancreatic cancerClonal relationshipBranch duct lesionsCystic precursor lesionsFamilial pancreatic cancerKRAS gene mutationsIntermediate dysplasiaIndependent genetic alterationsDuct lesionsClinicopathological characteristicsInvasive cancerPrecursor lesionsPartial pancreatectomyPatientsNeoplasmsIntermediate gradeGene mutationsCancerGenetic alterationsMolecular analysis
2011
Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent
Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, Hirose K, Schulick RD, Choti MA, Wolfgang CL, Pawlik TM. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 2011, 118: 2674-2681. PMID: 21935914, PMCID: PMC3578343, DOI: 10.1002/cncr.26553.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaConditional survivalConditional survival estimatesActuarial survivalCurative intentPositive marginsSurvival estimatesDuctal adenocarcinomaResection of PDACPostoperative year 5Date of surgeryCox regression analysisPredictors of survivalTime of surgeryMedian survivalMargin statusWorse survivalHigher lymphKaplan-MeierTumor sizeLarge cohortPatientsMultivariate analysisLymphSurgeryLoss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas
Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH, Goggins M. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Modern Pathology 2011, 24: 1237-1247. PMID: 21552209, PMCID: PMC3155013, DOI: 10.1038/modpathol.2011.74.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaE-cadherin expressionPancreatic adenocarcinomaDuctal adenocarcinomaIndependent predictorsPoor outcomeCox proportional hazards regression modelingProportional hazards regression modelingPancreatic cancer outcomesWorse median survivalResectable pancreatic adenocarcinomaMinority of patientsKaplan-Meier analysisE-cadherin statusMedian survivalSurgical resectionWorse prognosisCancer outcomesSubgroup analysisPathological factorsPatient outcomesCell adhesion moleculeMortality riskTissue microarrayPartial lossPresence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer
Matthaei H, Hong SM, Mayo SC, dal Molin M, Olino K, Venkat R, Goggins M, Herman JM, Edil BH, Wolfgang CL, Cameron JL, Schulick RD, Maitra A, Hruban RH. Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer. Annals Of Surgical Oncology 2011, 18: 3493-3499. PMID: 21537863, PMCID: PMC3166423, DOI: 10.1245/s10434-011-1745-9.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPancreatic intraepithelial neoplasiaResection marginsTransection marginR0 resectionIntraepithelial neoplasiaPanIN lesionsPanIN-3High-grade PanIN lesionsImportant clinicopathologic characteristicsPancreatic resection marginPancreatic transection marginPresence of PanINOverall median survivalIntraoperative frozen sectionSignificant survival differenceSignificant clinical implicationsGrades of PanINsR1 resectionStrong prognosticatorMedian survivalAdditional resectionClinicopathologic characteristicsClinicopathologic factorsSurgical margins
2010
The Effect of Steatosis on Echogenicity of Colorectal Liver Metastases on Intraoperative Ultrasonography
van Vledder MG, Torbenson MS, Pawlik TM, Boctor EM, Hamper UM, Olino K, Choti MA. The Effect of Steatosis on Echogenicity of Colorectal Liver Metastases on Intraoperative Ultrasonography. JAMA Surgery 2010, 145: 661-667. PMID: 20644129, DOI: 10.1001/archsurg.2010.124.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesIntraoperative ultrasonographyLiver metastasesTumor echogenicityLiver tissueExtent of steatosisEffect of steatosisCauses of steatosisFatty liver tissueJohns Hopkins HospitalNontumorous liver tissuesUltrasonography imagesSurgical therapyHistopathologic reviewLiver steatosisProspective studyHepatic steatosisSevere steatosisLiver surgeryPathological dataConspicuity of lesionsSteatosisPatientsEchogenicityUltrasonographyClinicopathologic Analysis of Ampullary Neoplasms in 450 Patients: Implications for Surgical Strategy and Long-Term Prognosis
Winter JM, Cameron JL, Olino K, Herman JM, de Jong MC, Hruban RH, Wolfgang CL, Eckhauser F, Edil BH, Choti MA, Schulick RD, Pawlik TM. Clinicopathologic Analysis of Ampullary Neoplasms in 450 Patients: Implications for Surgical Strategy and Long-Term Prognosis. Journal Of Gastrointestinal Surgery 2010, 14: 379-387. PMID: 19911239, DOI: 10.1007/s11605-009-1080-7.Peer-Reviewed Original ResearchConceptsLymph node metastasisAmpullary neoplasmsNode metastasisSurgical resectionTumor sizeInvasive adenocarcinomaMicroscopic vessel invasionInitial surgical procedureMedian tumor sizeOutcomes of patientsPoor histologic gradeLong-term prognosisSingle-institution databaseRegional lymph nodesAmpulla of VaterEarly invasive adenocarcinomaDepth of invasionMethodsBetween 1970Metastatic diseaseRadical resectionAmpullary adenomasClinicopathologic factorsLymph nodesClinicopathologic analysisPerineural invasion
2009
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH. SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer. Clinical Cancer Research 2009, 15: 4674-4679. PMID: 19584151, PMCID: PMC2819274, DOI: 10.1158/1078-0432.ccr-09-0227.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overFemaleGene DeletionHumansKaplan-Meier EstimateMaleMiddle AgedMutationPancreatic NeoplasmsPrognosisProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaSmad4 ProteinTumor Suppressor Protein p53ConceptsPoor prognosisPancreatic cancerLymph node statusShorter overall survivalSMAD4 gene mutationUnderwent pancreaticoduodenectomyOverall survivalMargin statusNode statusTumor sizePatient outcomesPatientsAdenocarcinomaPancreasCancerPrognosisGene mutationsSMAD4 inactivationGene inactivationSomatic mutationsHomozygous deletionMonthsSurvivalGenetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer
Blackford A, Parmigiani G, Kensler TW, Wolfgang C, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Klein A, Cameron JL, Olino K, Schulick R, Winter J, Vogelstein B, Velculescu VE, Kinzler KW, Hruban RH. Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer. Cancer Research 2009, 69: 3681-3688. PMID: 19351817, PMCID: PMC2669837, DOI: 10.1158/0008-5472.can-09-0015.Peer-Reviewed Original ResearchConceptsPancreatic cancerCigarette smokingGenetic Mutations AssociatedSomatic mutationsPancreatic cancer genomeCigarette smokersSmoking accountsPancreatic carcinomaDiscovery screenSmokersCarcinomaSmokingCancerMutations AssociatedMutational patternsAdenocarcinomaDriver genesPancreasCigarettesMore mutationsMutationsNonsynonymous mutationsNonsmokersPrevious studiesIndividuals
2007
Preoperative Chemotherapy for Colorectal Liver Metastases: Impact on Hepatic Histology and Postoperative Outcome
Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative Chemotherapy for Colorectal Liver Metastases: Impact on Hepatic Histology and Postoperative Outcome. Journal Of Gastrointestinal Surgery 2007, 11: 860-868. PMID: 17492335, DOI: 10.1007/s11605-007-0149-4.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesPreoperative chemotherapyHepatic colorectal metastasesHepatic injuryChemotherapy groupColorectal metastasesHepatic resectionLiver metastasesFluoropyrimidine-based regimensPerioperative complication rateMajority of patientsChemotherapy detailsEligible patientsChemotherapy regimenPerioperative morbidityComplication ratePostoperative outcomesClinicopathologic characteristicsLiver injurySinusoidal dilatationHepatic histologyNontumorous liverSuch injuriesChemotherapyPatients